Foghorn Historical Balance Sheet

FHTX Stock

USD 5.01 0.09 1.76%

Trend analysis of Foghorn Therapeutics balance sheet accounts such as Other Current Liabilities of 10.2 M or Total Current Liabilities of 87.8 M provides information on Foghorn Therapeutics' total assets, liabilities, and equity, which is the actual value of Foghorn Therapeutics to its prevalent stockholders. By breaking down trends over time using Foghorn Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Foghorn Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Foghorn Therapeutics is a good buy for the upcoming year.

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Foghorn Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.

About Foghorn Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Foghorn Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Foghorn Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Foghorn Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Foghorn currently owns. An asset can also be divided into two categories, current and non-current.

Foghorn Therapeutics Balance Sheet Chart

At this time, Foghorn Therapeutics' Other Current Liabilities is fairly stable compared to the past year. Total Current Liabilities is likely to rise to about 87.8 M in 2025, whereas Total Assets are likely to drop slightly above 280.8 M in 2025.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Foghorn Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Foghorn Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Foghorn Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Foghorn Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Foghorn Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Foghorn Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Foghorn Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.At this time, Foghorn Therapeutics' Other Current Liabilities is fairly stable compared to the past year. Total Current Liabilities is likely to rise to about 87.8 M in 2025, whereas Total Assets are likely to drop slightly above 280.8 M in 2025.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	51.5M	45.1M	51.8M	47.8M
Total Assets	404.9M	285.9M	328.8M	280.8M

Short Long Term Debt Total Total Assets

Foghorn Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Net Working Capital
Total Assets		0.87	0.66	0.63	0.42	0.9	0.72	0.93	-0.44	-0.83	0.77	0.69	0.94	0.75	0.6	0.91	0.86	0.81	0.74	0.82	0.93	0.93	0.41	0.95	1.0	0.99
Short Long Term Debt Total	0.87		0.71	0.48	0.55	0.69	0.86	0.98	-0.24	-0.76	0.75	0.57	0.98	0.56	0.53	0.93	0.82	0.85	0.57	0.98	0.91	0.71	0.58	0.79	0.84	0.83
Other Current Liab	0.66	0.71		0.43	-0.12	0.73	0.4	0.75	-0.15	-0.91	0.86	0.45	0.74	0.56	-0.11	0.75	0.8	0.8	0.62	0.78	0.83	0.72	-0.09	0.76	0.63	0.58
Total Current Liabilities	0.63	0.48	0.43		0.07	0.64	0.19	0.55	-0.94	-0.62	0.58	0.98	0.6	0.97	0.56	0.56	0.8	0.57	0.1	0.46	0.6	0.67	0.05	0.65	0.63	0.62
Total Stockholder Equity	0.42	0.55	-0.12	0.07		0.03	0.85	0.49	-0.11	0.06	-0.08	0.23	0.48	0.07	0.72	0.33	0.19	0.08	0.04	0.45	0.27	0.07	0.99	0.15	0.4	0.46
Other Liab	0.9	0.69	0.73	0.64	0.03		0.41	0.79	-0.43	-0.92	0.89	0.63	0.81	0.79	0.35	0.87	0.87	0.84	0.83	0.69	0.91	1.0	0.01	0.99	0.91	0.87
Net Tangible Assets	0.72	0.86	0.4	0.19	0.85	0.41		0.83	-0.06	-0.41	0.36	0.34	0.81	0.27	0.55	0.69	0.54	0.48	0.43	0.81	0.67	0.43	0.86	0.53	0.69	0.72
Property Plant And Equipment Net	0.93	0.98	0.75	0.55	0.49	0.79	0.83		-0.31	-0.82	0.8	0.63	1.0	0.65	0.52	0.96	0.88	0.87	0.66	0.97	0.96	0.81	0.51	0.88	0.91	0.9
Net Debt	-0.44	-0.24	-0.15	-0.94	-0.11	-0.43	-0.06	-0.31		0.36	-0.32	-0.92	-0.37	-0.88	-0.56	-0.32	-0.61	-0.28	0.12	-0.21	-0.36	-0.46	-0.06	-0.43	-0.44	-0.45
Retained Earnings	-0.83	-0.76	-0.91	-0.62	0.06	-0.92	-0.41	-0.82	0.36		-0.95	-0.62	-0.83	-0.75	-0.17	-0.87	-0.9	-0.91	-0.73	-0.79	-0.93	-0.92	0.06	-0.93	-0.82	-0.77
Accounts Payable	0.77	0.75	0.86	0.58	-0.08	0.89	0.36	0.8	-0.32	-0.95		0.56	0.81	0.71	0.17	0.91	0.89	0.95	0.72	0.81	0.92	0.88	-0.07	0.91	0.75	0.68
Cash	0.69	0.57	0.45	0.98	0.23	0.63	0.34	0.63	-0.92	-0.62	0.56		0.67	0.96	0.61	0.6	0.83	0.56	0.11	0.54	0.64	0.66	0.21	0.66	0.69	0.68
Non Current Assets Total	0.94	0.98	0.74	0.6	0.48	0.81	0.81	1.0	-0.37	-0.83	0.81	0.67		0.7	0.55	0.96	0.9	0.87	0.64	0.96	0.96	0.83	0.49	0.89	0.92	0.91
Non Currrent Assets Other	0.75	0.56	0.56	0.97	0.07	0.79	0.27	0.65	-0.88	-0.75	0.71	0.96	0.7		0.5	0.68	0.89	0.66	0.31	0.56	0.74	0.8	0.04	0.79	0.75	0.73
Other Assets	0.6	0.53	-0.11	0.56	0.72	0.35	0.55	0.52	-0.56	-0.17	0.17	0.61	0.55	0.5		0.47	0.4	0.35	0.11	0.4	0.39	0.41	0.69	0.41	0.61	0.65
Long Term Debt	0.91	0.93	0.75	0.56	0.33	0.87	0.69	0.96	-0.32	-0.87	0.91	0.6	0.96	0.68	0.47		0.9	0.94	0.73	0.94	0.98	0.88	0.34	0.92	0.88	0.85
Cash And Short Term Investments	0.86	0.82	0.8	0.8	0.19	0.87	0.54	0.88	-0.61	-0.9	0.89	0.83	0.9	0.89	0.4	0.9		0.85	0.54	0.85	0.94	0.87	0.19	0.91	0.84	0.81
Common Stock Shares Outstanding	0.81	0.85	0.8	0.57	0.08	0.84	0.48	0.87	-0.28	-0.91	0.95	0.56	0.87	0.66	0.35	0.94	0.85		0.69	0.87	0.91	0.85	0.11	0.88	0.79	0.74
Non Current Liabilities Total	0.74	0.57	0.62	0.1	0.04	0.83	0.43	0.66	0.12	-0.73	0.72	0.11	0.64	0.31	0.11	0.73	0.54	0.69		0.58	0.76	0.81	0.04	0.81	0.75	0.71
Other Current Assets	0.82	0.98	0.78	0.46	0.45	0.69	0.81	0.97	-0.21	-0.79	0.81	0.54	0.96	0.56	0.4	0.94	0.85	0.87	0.58		0.92	0.7	0.49	0.79	0.78	0.76
Other Stockholder Equity	0.93	0.91	0.83	0.6	0.27	0.91	0.67	0.96	-0.36	-0.93	0.92	0.64	0.96	0.74	0.39	0.98	0.94	0.91	0.76	0.92		0.92	0.28	0.96	0.91	0.88
Total Liab	0.93	0.71	0.72	0.67	0.07	1.0	0.43	0.81	-0.46	-0.92	0.88	0.66	0.83	0.8	0.41	0.88	0.87	0.85	0.81	0.7	0.92		0.06	0.99	0.93	0.9
Net Invested Capital	0.41	0.58	-0.09	0.05	0.99	0.01	0.86	0.51	-0.06	0.06	-0.07	0.21	0.49	0.04	0.69	0.34	0.19	0.11	0.04	0.49	0.28	0.06		0.14	0.39	0.45
Property Plant And Equipment Gross	0.95	0.79	0.76	0.65	0.15	0.99	0.53	0.88	-0.43	-0.93	0.91	0.66	0.89	0.79	0.41	0.92	0.91	0.88	0.81	0.79	0.96	0.99	0.14		0.95	0.91
Total Current Assets	1.0	0.84	0.63	0.63	0.4	0.91	0.69	0.91	-0.44	-0.82	0.75	0.69	0.92	0.75	0.61	0.88	0.84	0.79	0.75	0.78	0.91	0.93	0.39	0.95		1.0
Net Working Capital	0.99	0.83	0.58	0.62	0.46	0.87	0.72	0.9	-0.45	-0.77	0.68	0.68	0.91	0.73	0.65	0.85	0.81	0.74	0.71	0.76	0.88	0.9	0.45	0.91	1.0

Click cells to compare fundamentals

Foghorn Therapeutics Account Relationship Matchups

Foghorn Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	255.6M	519.8M	404.9M	285.9M	328.8M	280.8M
Short Long Term Debt Total	82.0M	58.3M	51.5M	45.1M	51.8M	47.8M
Other Current Liab	5.2M	2.6M	5.0M	8.4M	9.7M	10.2M
Total Current Liabilities	18.8M	48.7M	336.8M	58.4M	67.2M	87.8M
Total Stockholder Equity	146.2M	96.9M	112K	(77.2M)	(88.8M)	(84.3M)
Net Tangible Assets	(88.0M)	146.2M	96.9M	112K	128.8K	122.4K
Property Plant And Equipment Net	62.3M	56.1M	49.4M	42.9M	49.3M	39.7M
Net Debt	(10.8M)	(42.8M)	(294.3M)	(35.3M)	(31.7M)	(33.3M)
Retained Earnings	(162.9M)	(264.3M)	(373.1M)	(471.6M)	(424.4M)	(403.2M)
Accounts Payable	3.7M	3.8M	5.4M	6.3M	7.2M	4.5M
Cash	92.8M	101.1M	345.8M	80.3M	92.4M	123.8M
Non Current Assets Total	64.9M	60.2M	59.1M	45.7M	52.6M	43.6M
Non Currrent Assets Other	842K	2.4M	8.0M	2.8M	3.2M	2.7M
Other Assets	2.6M	4.1M	4.1M	1.0	1.15	1.09
Cash And Short Term Investments	185.8M	154.3M	345.8M	234.1M	269.2M	178.7M
Common Stock Shares Outstanding	36.8M	37.2M	41.6M	42.0M	48.3M	39.2M
Liabilities And Stockholders Equity	255.6M	519.8M	404.9M	285.9M	328.8M	280.8M
Non Current Liabilities Total	90.6M	374.2M	68.0M	304.7M	350.4M	185.9M
Capital Lease Obligations	62.3M	58.3M	51.5M	45.1M	51.8M	40.1M
Other Current Assets	9.8M	5.3M	5.6M	6.1M	7.0M	5.2M
Other Stockholder Equity	309.1M	361.1M	377.2M	395.2M	454.5M	266.4M
Total Liab	109.4M	422.9M	404.8M	363.1M	417.6M	273.7M
Net Invested Capital	165.8M	96.9M	112K	(77.2M)	(69.5M)	(66.0M)
Property Plant And Equipment Gross	19.5M	61.4M	58.0M	54.9M	63.2M	36.6M
Total Current Assets	190.7M	459.6M	345.8M	240.2M	276.2M	237.1M
Accumulated Other Comprehensive Income	(7K)	(10K)	(4.0M)	(826K)	(949.9K)	(997.4K)
Net Working Capital	171.8M	410.9M	296.2M	181.7M	209.0M	202.0M
Property Plant Equipment	3.7M	62.3M	56.1M	49.4M	56.8M	38.2M
Current Deferred Revenue	2.0M	28.3M	336.8M	34.6M	39.7M	37.7M
Short Term Debt	8.0M	14.0M	11.9M	8.8M	10.1M	10.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for Foghorn Stock Analysis

When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Foghorn Historical Balance Sheet

About Foghorn Balance Sheet Analysis

Foghorn Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Foghorn Therapeutics balance sheet Correlations

Foghorn Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Foghorn Therapeutics balance sheet Accounts

Also Currently Popular

Additional Tools for Foghorn Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Other Liab
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Net Working Capital	+ 1.0	Total Current Assets
Net Working Capital	+ 0.99	Total Assets
Net Invested Capital	+ 0.99	Total Stockholder Equity

Accounts Payable	- 0.95	Retained Earnings
Net Debt	- 0.94	Total Current Liabilities
Property Plant And Equipment Gross	- 0.93	Retained Earnings
Other Stockholder Equity	- 0.93	Retained Earnings
Total Liab	- 0.92	Retained Earnings
Cash	- 0.92	Net Debt